V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330003804 | 330001914 | 1.81 | null | Curative (C) | 2015-05-26 | 2015-05-20 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330014234 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003805 | 330001914 | 0 | 54.8 | Curative (C) | 2013-08-01 | 2013-08-03 | Cetuximab + Radiotherapy Load | 02 | null | 330014234 | CETUXIMAB + RT |
| 330003806 | 330009806 | 1.7 | 56.6 | Curative (C) | 2016-05-30 | 2016-06-21 | CETUXIMAB + RT | N | Y | 330014266 | CETUXIMAB + RT |
| 330003807 | 330009806 | 1.8 | 77 | Neo-adjuvant (N) | 2014-10-29 | 2014-11-05 | EURAMOS TRIAL | 02 | N | 330014266 | EURAMOS TRIAL |
| 330003808 | 330009806 | null | 36.2 | Palliative (P) | 2016-02-08 | 2016-02-29 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 330014266 | CARBO + FLUOROURACIL |
| 330003809 | 330009806 | 1.53 | 62.75 | Palliative (P) | 2015-01-16 | 2015-01-29 | Cisplatin + Etoposide po | 02 | N | 330014266 | CISPLATIN + ETOPOSIDE |
| 330003810 | 330012952 | 1.7 | 72 | Curative (C) | 2017-05-12 | 2017-05-13 | EURAMOS TRIAL | N | N | 330014292 | EURAMOS TRIAL |
| 330003811 | 330012952 | 1.64 | 53.6 | Curative (C) | 2016-09-21 | 2016-10-16 | OST Euramos 1 Closed Trial - AP | N | N | 330014292 | MAP |
| 330003812 | 330012952 | 1.7 | 69.2 | Palliative (P) | 2015-05-31 | 2015-06-15 | CAP | N | Y | 330014292 | CAP |
| 330003813 | 330001915 | 1.77 | 100 | null | 2012-09-06 | 2012-09-06 | DA 3 + 10 | 02 | N | 330014334 | DA |
| 330003814 | 330001915 | 1.89 | 41.8 | Curative (C) | 2013-09-10 | 2013-09-15 | CETUXIMAB + RT | N | Y | 330014334 | CETUXIMAB + RT |
| 330003815 | 330001916 | null | 85 | Adjuvant (A) | 2014-02-06 | 2014-02-13 | PAM | N | N | 330014340 | MAP |
| 330003816 | 330001916 | 1.69 | 67.2 | Palliative (P) | 2016-09-10 | 2016-09-11 | CAP | 02 | N | 330014340 | CAP |
| 330003817 | 330001916 | 1.63 | null | Neo-adjuvant (N) | 2017-03-28 | 2017-04-02 | EURAMOS TRIAL | null | N | 330014340 | EURAMOS TRIAL |
| 330003818 | 330011348 | 1.67 | 64.1 | Neo-adjuvant (N) | 2015-03-19 | 2015-03-20 | MAP | N | N | 330014355 | MAP |
| 330003819 | 330011348 | 1.7 | 71.7 | null | 2016-10-02 | 2016-10-02 | CYCLOPHOSPHAMIDE + RITUXIMAB | 2 | N | 330014355 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003820 | 330001917 | 1.67 | null | Palliative (P) | 2013-06-14 | 2013-06-30 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330014365 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330003821 | 330007040 | 1.77 | 23 | Neo-adjuvant (N) | 2014-09-01 | 2014-09-09 | MAP | N | N | 330014373 | MAP |
| 330003822 | 330009808 | 1.66 | 49.7 | Curative (C) | null | 2014-04-16 | DA 3 + 10 | null | null | 330014375 | DA |
| 330003823 | 330009808 | 1.57 | 36.2 | Neo-adjuvant (N) | null | 2013-12-11 | EURAMOS TRIAL | null | null | 330014375 | EURAMOS TRIAL |
| 330003824 | 330009808 | null | 82.4 | Curative (C) | 2017-10-01 | 2017-10-01 | CETUXIMAB | N | null | 330014375 | CETUXIMAB |
| 330003825 | 330001918 | 1.8 | 87.2 | Palliative (P) | 2015-01-27 | 2015-02-03 | CAP | N | N | 330014393 | CAP |
| 330003826 | 330001918 | 1.75 | null | Palliative (P) | 2013-11-16 | 2013-11-26 | Cisplatin + Etoposide po&iv 3 day | null | N | 330014393 | CISPLATIN + ETOPOSIDE |
| 330003827 | 330001918 | 1.66 | 65.7 | Palliative (P) | 2013-07-20 | 2013-07-20 | CAP | null | null | 330014393 | CAP |
| 330003828 | 330001918 | 1.98 | 57 | Neo-adjuvant (N) | 2013-12-17 | 2013-12-18 | CISPLATIN + GEMCITABINE | N | N | 330014393 | CISPLATIN + GEMCITABINE |
| 330003829 | 330001919 | 1.73 | 67.6 | Neo-adjuvant (N) | 2014-06-21 | 2014-06-25 | EURAMOS TRIAL | N | N | 330014444 | EURAMOS TRIAL |
| 330003830 | 330001919 | null | null | Curative (C) | null | 2013-12-24 | Cetuximab 7 day (Cycle 1) | N | Y | 330014444 | CETUXIMAB |
| 330003831 | 330001919 | 1.79 | 82.7 | Curative (C) | 2017-05-25 | 2017-05-25 | CISPLATIN + ETOPOSIDE | 1 | N | 330014444 | CISPLATIN + ETOPOSIDE |
| 330003832 | 330001919 | 1.63 | 65.6 | Curative (C) | 2013-03-16 | 2013-03-16 | OST Euramos 1 Closed Trial - AP | null | null | 330014444 | MAP |
| 330003833 | 330001919 | 1.54 | 89.2 | null | 2015-12-31 | 2016-01-12 | Carbo F | N | N | 330014444 | CARBO + FLUOROURACIL |
| 330003834 | 330001920 | 1.66 | 59.8 | Not known (9) | 2017-10-04 | 2017-10-04 | CETUXIMAB + RT | 02 | null | 330014477 | CETUXIMAB + RT |
| 330003835 | 330001920 | 1.64 | 50 | Adjuvant (A) | 2013-04-04 | 2013-05-02 | Carbo F | 2 | Y | 330014477 | CARBO + FLUOROURACIL |
| 330003836 | 330001920 | 1.84 | 78.2 | Curative (C) | 2016-08-30 | 2016-09-06 | Cetuximab + Radiotherapy Load | N | Y | 330014477 | CETUXIMAB + RT |
| 330003837 | 330001921 | 0 | 53.5 | Curative (C) | 2014-07-29 | 2014-08-09 | OST Euramos 1 Closed Trial - AP | Y | N | 330014487 | MAP |
| 330003838 | 330001922 | 1.47 | 72.4 | Palliative (P) | 2017-06-19 | 2017-07-23 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 330014489 | CARBO + FLUOROURACIL |
| 330003839 | 330001923 | 1.6 | 75.6 | Palliative (P) | null | 2017-09-09 | CAP | null | null | 330014492 | CAP |
| 330003840 | 330001923 | 1.66 | 73.8 | null | 2013-05-22 | 2013-05-28 | CVP R | N | N | 330014492 | CVP R |
| 330003841 | 330001923 | 1.63 | 58.4 | Palliative (P) | 2013-01-25 | 2013-02-07 | Cisplatin + Etoposide po&iv 3 day | N | N | 330014492 | CISPLATIN + ETOPOSIDE |
| 330003842 | 330001923 | 0 | 73.2 | Adjuvant (A) | 2014-01-26 | 2014-01-26 | DA 3 + 10 | 02 | null | 330014492 | DA |
| 330003843 | 330001923 | 1.86 | 98.9 | Adjuvant (A) | 2015-09-13 | 2015-10-01 | EW EuroEwing 2012 Arm A VIDE | N | N | 330014492 | EURO-EWING |
| 330003844 | 330001924 | 1.7 | 74.4 | Curative (C) | 2015-07-11 | 2015-07-12 | DA | N | N | 330014529 | DA |
| 330003845 | 330007045 | 1.76 | 61 | Curative (C) | 2013-10-12 | 2013-10-14 | CVP R | 2 | null | 330014531 | CVP R |
| 330003846 | 330007045 | 1.85 | 74.1 | Curative (C) | 2017-07-05 | 2017-07-05 | MAP | null | null | 330014531 | MAP |
| 330003847 | 330001925 | 1.75 | 79.2 | Adjuvant (A) | 2017-05-22 | 2017-06-01 | CAP | N | N | 330014539 | CAP |
| 330003850 | 330001927 | 1.65 | 61.2 | Adjuvant (A) | 2013-06-22 | 2013-07-07 | EURAMOS TRIAL | N | N | 330014546 | EURAMOS TRIAL |
| 330003851 | 330001927 | null | null | Neo-adjuvant (N) | 2015-12-23 | 2015-12-23 | EURO-EWING | N | N | 330014546 | EURO-EWING |
| 330003852 | 330001928 | 1.68 | 96.4 | Adjuvant (A) | 2015-12-04 | 2015-12-31 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 330014558 | CISPLATIN + GEMCITABINE |
| 330003853 | 330001928 | 1.73 | 81 | Adjuvant (A) | 2017-06-16 | 2017-06-17 | CAP | N | N | 330014558 | CAP |
| 330003854 | 330001928 | 1.91 | null | Neo-adjuvant (N) | 2014-11-28 | 2014-12-04 | EW EuroEwing 2012 Arm A VIDE | 2 | N | 330014558 | EURO-EWING |
| 330003855 | 330001928 | 1.68 | 39.8 | Palliative (P) | 2016-05-20 | 2016-05-25 | CISPLATIN + GEMCITABINE | Y | N | 330014558 | CISPLATIN + GEMCITABINE |